StreetInsider.com News Articles

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Thu, 16 Jul 2026 15:22:00 -0400

Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing
Supports iMDx's commercial strategy in transplant monitoring
Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories
Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry

NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care.

The company believes the updated policy, known as a local coverage

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Thu, 16 Jul 2026 15:22:00 -0400

Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing
Supports iMDx's commercial strategy in transplant monitoring
Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories
Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry

The company believes the updated policy, known as a local coverage

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Thu, 16 Jul 2026 15:22:00 -0400

Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing
Supports iMDx's commercial strategy in transplant monitoring
Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories
Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry

The company believes the updated policy, known as a local coverage

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Thu, 16 Jul 2026 15:22:00 -0400

Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing
Supports iMDx's commercial strategy in transplant monitoring
Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories
Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry

The company believes the updated policy, known as a local coverage

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Thu, 16 Jul 2026 15:22:00 -0400

Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing
Supports iMDx's commercial strategy in transplant monitoring
Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories
Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry

The company believes the updated policy, known as a local coverage

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Thu, 16 Jul 2026 15:22:00 -0400

Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing
Supports iMDx's commercial strategy in transplant monitoring
Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories
Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry

The company believes the updated policy, known as a local coverage

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Thu, 16 Jul 2026 15:22:00 -0400

Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing
Supports iMDx's commercial strategy in transplant monitoring
Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories
Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry

The company believes the updated policy, known as a local coverage

Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio

Thu, 16 Jul 2026 15:22:00 -0400

Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing
Supports iMDx's commercial strategy in transplant monitoring
Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories
Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry

The company believes the updated policy, known as a local coverage

Form 4 Insight Molecular Diagno For: Jul 01 Filed by: SILVERMAN LOU

Mon, 06 Jul 2026 20:40:00 -0400

si-local-file:///var/storage/secattach/20260706/26737168.html

Form 4 Insight Molecular Diagno For: Jul 01 Filed by: SILVERMAN LOU

Mon, 06 Jul 2026 20:40:00 -0400

si-local-file:///var/storage/secattach/20260706/26737168.html

Form 4 Insight Molecular Diagno For: Jul 01 Filed by: Last Andrew J.

Mon, 06 Jul 2026 20:38:00 -0400

si-local-file:///var/storage/secattach/20260706/26737162.html

Form 4 Insight Molecular Diagno For: Jul 01 Filed by: Last Andrew J.

Mon, 06 Jul 2026 20:38:00 -0400

si-local-file:///var/storage/secattach/20260706/26737162.html

Form 4 Insight Molecular Diagno For: Jul 01 Filed by: Arno Andrew

Mon, 06 Jul 2026 20:36:00 -0400

si-local-file:///var/storage/secattach/20260706/26737157.html

Form 4 Insight Molecular Diagno For: Jul 01 Filed by: Arno Andrew

Mon, 06 Jul 2026 20:36:00 -0400

si-local-file:///var/storage/secattach/20260706/26737157.html

IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper

Mon, 29 Jun 2026 08:00:00 -0400

Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58
Recent studies advanced science of molecular diagnostic testing for transplanted organ rejection, published in Clinical Chemistry, Transplant International, American Journal of Transplantation and Nephrology Dialysis Transplantation, among others

NASHVILLE, Tenn., June 29, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that its Chief Science Officer, Prof. Dr. Ekkehard Schuetz. M.D., Ph.D., has published his 200th scientific article.

Dr. Schuetz and Dr.

IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper

Mon, 29 Jun 2026 08:00:00 -0400

Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58
Recent studies advanced science of molecular diagnostic testing for transplanted organ rejection, published in Clinical Chemistry, Transplant International, American Journal of Transplantation and Nephrology Dialysis Transplantation, among others

Dr. Schuetz and Dr.

IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper

Mon, 29 Jun 2026 08:00:00 -0400

Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58
Recent studies advanced science of molecular diagnostic testing for transplanted organ rejection, published in Clinical Chemistry, Transplant International, American Journal of Transplantation and Nephrology Dialysis Transplantation, among others

Dr. Schuetz and Dr.

IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper

Mon, 29 Jun 2026 08:00:00 -0400

Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58
Recent studies advanced science of molecular diagnostic testing for transplanted organ rejection, published in Clinical Chemistry, Transplant International, American Journal of Transplantation and Nephrology Dialysis Transplantation, among others

Dr. Schuetz and Dr.

iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant

Mon, 22 Jun 2026 14:07:00 -0400

-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation-

NASHVILLE, Tenn., June 22, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), and the American Society of Transplant Surgeons (ASTS) today announced the selection of Kenneth Andreoni, MD, Surgical Director of Kidney Transplantation at Thomas Jefferson University, and Kenneth Chavin, MD, MBA, PhD, FACS, of Temple Health, as the recipients of the ASTS-iMDx Research Grant for Understanding the Health Economics of In-House versus Send-Out of donor-derived cell-free DNA (dd-cfDNA) testing. The pursuit of this research is timely as the

iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant

Mon, 22 Jun 2026 14:07:00 -0400

-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation-

iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant

Mon, 22 Jun 2026 14:07:00 -0400

-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation-

iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant

Mon, 22 Jun 2026 14:07:00 -0400

-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation-

iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant

Mon, 22 Jun 2026 14:07:00 -0400

-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation-

iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant

Mon, 22 Jun 2026 14:07:00 -0400

-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation-

iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant

Mon, 22 Jun 2026 14:07:00 -0400

-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation-